source
- Repligen to acquire BioLife Solutions for $1.5 billion as BeOne announces $300 million US expansionRepligen announced it will acquire cell‑processing services provider BioLife Solutions in a transaction valued at roughly $1.5 billion. The deal adds BioLife’s platform to Repligen’s portfolio of b…
- Eli Lilly's retatrutide shows strong weight loss but no clear heart risk reduction in Phase 3 trialEli Lilly released new data from a Phase 3 trial of retatrutide, its next‑generation obesity drug. The study enrolled nearly 2,000 participants with severe obesity and existing heart disease, some…